Executive Interview – ReNeuron

ReNeuron is a UK biotech company developing allogeneic (off-the-shelf) novel stem cell therapies to address debilitating conditions with significant unmet clinical needs. Neural stem cell-based products, developed from an immortalised CTX single cell line, are in clinical studies: ReN001 in Phase II aimed at improving disability in ischaemic stroke patients and ReN009 in Phase I for critical limb ischaemia. ReN003, derived from human retinal progenitor cells, will enter a Phase I/II study for retinitis pigmentosa by H215.

CFO Michael Hunt outlines the company’s cell-based technology platforms and highlights the potential clinical data catalysts that investors should watch out for over the next 12-18 months. He also comments on the company’s solid financial position, which enables the development of its multiple products to their next valuation inflection points, with Neil Woodford of Woodford Investment Management now a cornerstone investor (19.9% stake).